21 November 2013 – Effective 15 November 2013, British Columbia is the first province in Canada to include Zytiga (abiraterone acetate) on its public formulary for men living with metastatic prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

For more details, go to: http://www.janssen.ca/media